HER2-Altered Advanced NSCLC Treatment Moves Toward First-Line and Combination Regimens

Precision therapy for advanced non-small cell lung cancer (NSCLC) with HER2 mutations or overexpression is advancing rapidly. Treatment has centered on antibody-drug conjugates in later-line settings, but the field is now shifting toward first-line regimens and combination strategies. HER2 tyrosine kinase inhibitors are also expanding the range of options available to clinicians. Together, these developments are reshaping how HER2-altered advanced NSCLC is managed, moving targeted treatment earlier in the disease course. Key open questions include which first-line and combination approaches will establish themselves as standard of care and how HER2 TKIs will be positioned relative to antibody-drug conjugates.

Written by a model from the reports · updated 3 hours ago